Methylprednisolone
- PDF / 169,676 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 61 Downloads / 171 Views
1 S
Treatment failure in acute graft-versus-host disease: 29 case reports In a retrospective multi-center study conducted in France between March 2014 and January 2017, 29 patients aged 0.6–14.5 years [sexes not stated] were described, who exhibited treatment failure during treatment with methylprednisolone for acute graft-versus-host disease [aGVHD; routes and exact doses not stated]. The patients underwent allogeneic haematopoietic stem cell transplantation under unspecified GVHD prophylactic therapy. Subsequently, the patients developed aGVHD with involvement of skin, lung, liver, bone marrow, kidneys or gastrointestinal region. Therefore, the patients were treated with methylprednisolone ≥1 mg/kg/day. However, the patients exhibited resistance to the methylprednisolone therapy (steroid-refractory aGVHD), indicating treatment failure. Thus, methylprednisolone was discontinued. Further, the patients started receiving off-label oral ruxolitinib 5–20 mg/day (6.3–28.7 mg/m2/day) tablet at day 1. Ruxolitinib was given two times a day. Laisne L, et al. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC. Pediatric 803517974 Blood and Cancer 67: No. 9, Sep 2020. Available from: URL: http://doi.org/10.1002/pbc.28233
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
